Investigating how PARP1 affects myelin formation and repair in the brain.
The curious case of PARP1 in CNS myelin formation and repair
This study is looking at a protein called PARP1 to see how it helps certain brain cells develop and repair the protective covering around nerves, which is important for people with multiple sclerosis, and aims to find new ways to help them recover from nerve damage.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-10873283 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of PARP1, a protein involved in DNA repair, in the differentiation of oligodendrocyte progenitor cells (OPCs) and the formation of myelin in the central nervous system. It aims to explore how PARP1 can be targeted to promote remyelination, which is crucial for patients with multiple sclerosis (MS) who experience neurological progression due to myelin damage. By studying the mechanisms of PARP1, the research seeks to identify new therapeutic strategies that could work alongside existing anti-inflammatory treatments to improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with multiple sclerosis, particularly those experiencing neurological decline due to myelin damage.
Not a fit: Patients with demyelinating disorders other than multiple sclerosis or those without significant neurological symptoms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that enhance myelin repair in patients with multiple sclerosis, potentially slowing disease progression and improving neurological function.
How similar studies have performed: Previous research has shown promise in targeting similar pathways for remyelination, indicating that this approach could yield significant advancements in treatment.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Guo, Fuzheng — University of California at Davis
- Study coordinator: Guo, Fuzheng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.